Related Experiment Video
Updated: Feb 20, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
CDK5 in oncology: recent advances and future prospects
Jimma Likisa Lenjisa1, Solomon Tadesse1, Nishat Zareen Khair1
1Centre for Drug Discovery & Development, Sansom Institute for Health Research, School of Pharmacy & Medical Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Abstract:
Selective abrogation of cyclin-dependent kinases (CDK) activity is a highly promising strategy in cancer treatment. The atypical CDK, CDK5 has long been known for its role in neurodegenerative diseases, and is becoming an attractive drug target for cancer therapy. Myriads of recent studies have uncovered that aberrant expression of CDK5 contributes to the oncogenic initiation and progression of multiple solid and hematological malignancies. CDK5 is also implicated in the regulation of cancer stem cell biology. In this review, we present the current state of knowledge of CDK5 as a druggable target for cancer treatment. We also provide a detailed outlook of designing selective and potent inhibitors of this enzyme.
Insights
Targeting cyclin-dependent kinases (CDK) is key for cancer therapy. This review focuses on CDK5 (cyclin-dependent kinase 5), exploring its role in cancer and potential as a drug target for developing novel cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) are critical regulators of the cell cycle, and their dysregulation is implicated in cancer.
- CDK5, traditionally known for its role in neurobiology, is increasingly recognized for its involvement in various cancers.
- Aberrant CDK5 expression is linked to the initiation and progression of both solid tumors and hematological malignancies, as well as cancer stem cell regulation.
Purpose of the Study:
- To review the current understanding of CDK5 as a potential therapeutic target in cancer treatment.
- To highlight the role of CDK5 in oncogenesis and cancer stem cell biology.
- To provide insights into the development of selective CDK5 inhibitors for cancer therapy.
Main Methods:
- Literature review of recent studies on CDK5 in cancer.
- Analysis of CDK5's role in different cancer types and cancer stem cell regulation.
- Discussion of strategies for designing potent and selective CDK5 inhibitors.
Main Results:
- CDK5 plays a significant role in the development and progression of multiple cancers.
- CDK5 is implicated in the maintenance and function of cancer stem cells.
- The development of selective CDK5 inhibitors presents a promising therapeutic avenue.
Conclusions:
- CDK5 is an attractive and druggable target for novel cancer therapies.
- Targeting CDK5 may offer a new strategy for treating various malignancies, including those resistant to conventional therapies.
- Further research into selective CDK5 inhibition is warranted to translate this potential into clinical benefits.
Related Concept Videos
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Positive Regulator Molecules
Cancer

